Human betaherpesvirus 5
| Artesunate | CMV | Unclear | Phase 3 | — | Unknown | |
| Brincidofovir | CMV | Viral DNA polymerase inhibitor | Phase 3 | — | Viral DNA pol | |
| Cidofovir | CMV | Viral DNA polymerase inhibitor | FDA approved | FDA | Viral DNA pol | |
| Foscarnet | CMV | Pyrophosphate analog DNA polymerase inhibitor | FDA approved | FDAJapan | Viral DNA pol | |
| Ganciclovir | CMV | Viral RNA polymerase inhibitor | FDA approved | FDAJapanChina | Viral DNA pol | |
| Acyclovir | CMV | Viral DNA polymerase inhibitor | Approved (other) | JapanChinaRussia | Viral DNA pol | |
| AVN-944 | CMV | IMPDH inhibitor | Preclinical | — | Human IMPDH | |
| Berberine | CMV | AMP-activated protein kinase (AMPK) activator | Preclinical | — | Unknown | |
| Calanolide A | CMV | Human (multiple) | Preclinical | — | Human (multiple) | |
| Cyclosporine | CMV | Calcineurin inhibitor; allows for inhibition of T cell activation | Preclinical | — | Human CYPs | |
| Docosanol | CMV | Inhibition of fusion | Preclinical | — | Viral glycoprotein | |
| Eflornithine | CMV | Enzyme-activated; irreversible inhibitor of ornithine decarboxylase | Preclinical | — | Human ODC | |
| Emetine | CMV | — | Preclinical | — | Human ribosome | |
| Emodin | CMV | — | Preclinical | — | Human (multiple) | |
| Fiacitabine | CMV | Inhibits viral DNA synthesis | Preclinical | — | Viral DNA pol | |
| Filociclovir | CMV | Dual DNA polymerase/kinase inhibitor; Nucleoside analog | Preclinical | — | Viral DNA pol | |
| Gefitinib | CMV | EGFR inhibitor | Preclinical | — | Human PTK | |
| Labyrinthopeptin A1 | CMV | Interference with viral phospholipid membrane | Preclinical | — | Viral membrane | |
| Labyrinthopeptin A2 | CMV | viral membrane lipid phosphatidylethanolamine | Preclinical | — | Viral membrane | |
| Leflunomide | CMV | Pyrimidine synthesis inhibitor | Preclinical | — | Human DHODH | |
| Lobucavir | CMV | — | Preclinical | — | Viral DNA pol | |
| Manidipine | CMV | Calcium channel blocker | Preclinical | — | Human ion channel | |
| Merimepodib | CMV | IMPDH inhibitor | Preclinical | — | Human IMPDH | |
| Monensin | CMV | — | Preclinical | — | Unknown | |
| Nitroprusside | CMV | Nitrix oxide donor | Preclinical | — | Human NPR1 |